Exchange: OTC·Updated 02:35 PM EDT

MDNAF Medicenna Therapeutics Corp

$0.346
$0.004
(1.14%)
Today
Reported EarningsAug 14
Mkt Cap$26.86M
Vol13,647.00

About MDNAF

Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. It engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.
40

Bearish Sentiment

How do you feel about MDNAF?

Advertisement|Remove ads.